DGAP-News

RedHill Biopharma Ltd.: RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program

DGAP-News: RedHill Biopharma Ltd. / Key word(s): Patent
RedHill Biopharma Ltd.: RedHill Biopharma Receives Notice of Allowance of
Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program

10.02.2016 / 18:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press Release

RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent
Covering RHB-104 Phase III Crohn's Disease Program

- Once granted, the new U.S. patent covering methods of use for RHB-104
is expected to be valid through 2029

- RHB-104 is undergoing a first Phase III study for the treatment of
Crohn's disease in the U.S. and additional countries, with interim
analysis expected during the second half of 2016

- A Phase IIa proof-of-concept study evaluating RHB-104 in patients
treated for relapsing-remitting multiple sclerosis is ongoing, with
top-line interim results expected in the coming weeks

TEL-AVIV, Israel, February 10, 2016 RedHill Biopharma Ltd. (NASDAQ/TASE:
RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company
primarily focused on the development and commercialization of late
clinical-stage, proprietary, orally-administered, small molecule drugs for
inflammatory and gastrointestinal diseases, including cancer, today
announced that it has received a Notice of Allowance from the United States
Patent and Trademark Office (USPTO) for a new patent covering RHB-104.

RHB-104 is a proprietary and potentially groundbreaking antibiotic
combination therapy in oral capsule formulation, with potent intracellular,
anti-mycobacterial and anti-inflammatory properties, currently undergoing a
first Phase III study for Crohn's disease and a Phase IIa study for
multiple sclerosis.

The patent application, entitled "Compositions Comprising Rifabutin,
Clarithromycin, and Clofazamine and Uses Therof" significantly expands
RedHill's patent portfolio covering RHB-104 and is expected to be valid
until 2029 once granted. Upon issuance, RedHill will hold five U.S. patents
and multiple international patents for RHB-104.

Danielle Abramson, Ph.D., RedHill's Director of Intellectual Property &
Research said: "We are very pleased to announce this new addition to
RedHill's already robust patent portfolio covering RHB-104. The Phase III
study with RHB-104 for Crohn's disease, currently ongoing in the U.S. and
additional countries, is advancing well, with interim analysis expected in